{"product_id":"akebia-marketing-mix","title":"Akebia Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Akebia’s product pipeline, strategic pricing, targeted distribution, and focused promotions combine to support its market position and growth objectives; the preview highlights key moves, but the full 4Ps Marketing Mix Analysis delivers the complete, editable, presentation-ready breakdown you need to benchmark, plan, or pitch—get instant access and save hours of research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVafseo Oral HIF-PH Inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo, Akebia Therapeutics’ oral HIF-PH inhibitor, is the company’s lead therapy for anemia due to chronic kidney disease in adults on dialysis, launched in the US in 2023 and achieving estimated 2025 net sales of ~$220 million. It offers an oral physiological alternative to injectable erythropoiesis-stimulating agents by stabilizing HIF (hypoxia-inducible factor) to increase endogenous erythropoietin and iron availability. Clinical data showed noninferior hemoglobin maintenance versus ESAs with fewer IV iron doses in pivotal trials; pricing targets reflect parity with ESA cost per patient annually (~$12–18k).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuryxia Ferric Citrate Tablets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAuryxia (ferric citrate) tablets target serum phosphorus control in adult dialysis-dependent CKD and treat iron-deficiency anemia in non-dialysis CKD adults, letting Akebia address two major CKD complications with one oral drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIF Biology Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia leverages a hypoxia-inducible factor (HIF) research platform to develop therapies beyond anemia, targeting tissue oxygen-sensing pathways linked to renal and metabolic complications.\u003c\/p\u003e\n\u003cp\u003eHIF-focused programs aim to expand into chronic kidney disease (CKD) and diabetic complications where oxygen regulation matters; AKB-5169 and pipeline progression funded by $120M cash (Q4 2025 guidance) accelerate IND-enabling work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Oral Delivery Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa core feature of akebia therapeutics product strategy is oral administration to cut injection burden for chronic kidney disease patients aiming improve adherence amid dialysis routines in akb-9778 trials reported a higher proxy versus injectables real-world claims analyses.\u003e\n\u003cpthe oral design emphasizes simple dosing and compatibility with complex regimens pill counts once-daily options reduce missed doses hospitalization risk where poor adherence raises by in dialysis cohorts.\u003e\n\u003cpthis delivery format differentiates akebia from injectable erythropoiesis-stimulating agents supporting market positioning as a patient-centric alternative in renal worth\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral dosing cuts injection visits and needle-related barriers\u003c\/li\u003e\n\u003cli\u003e12% higher adherence proxy vs injectables (2024 claims data)\u003c\/li\u003e\n\u003cli\u003eTargets dialysis patients where nonadherence ups hospitalizations ~20%\u003c\/li\u003e\n\u003cli\u003eSupports entry into a renal market ≈ $6.5B (2025 estimate)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Expansion Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpakebia continues evaluating hif-ph inhibitors for acute kidney injury and ischemic diseases to diversify revenue meet unmet needs the pipeline is preclinical early clinical as of with r spend in supporting this effort.\u003e\n\u003cpdevelopment follows a data-driven expansion of hif-ph expertise aiming to leverage existing ip and reduce time-to-proof by using translational biomarkers adaptive trial designs.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget areas: acute kidney injury, ischemic diseases\u003c\/li\u003e\n\u003cli\u003eStage: research to early clinical (2025)\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: ~$45 million\u003c\/li\u003e\n\u003cli\u003eStrategy: translational biomarkers, adaptive trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdevelopment\u003e\u003c\/pakebia\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Vafseo Drives Akebia Growth: $220M 2025 Sales, Auryxia + CKD Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia’s product mix centers on oral HIF-PH inhibitor Vafseo (lead anemia in dialysis launch 2023; est. 2025 sales ~$220M) and Auryxia for phosphate\/iron control, leveraging oral dosing to boost adherence (~12% higher) and cut injection burden; pipeline targets CKD\/ischemic indications with 2024 R\u0026amp;D ~$45M and cash guidance ~$120M (Q4 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVafseo\u003c\/td\u003e\n\u003ctd\u003e$220M sales\u003c\/td\u003e\n\u003ctd\u003eoral HIF-PH, dialysis anemia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryxia\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003ephosphate+iron, CKD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/Cash\u003c\/td\u003e\n\u003ctd\u003e$45M\/$120M\u003c\/td\u003e\n\u003ctd\u003e2024 spend\/Q4 2025 cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Akebia’s Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of marketing positioning grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Akebia’s 4P marketing insights into a concise, leadership-ready snapshot that eases strategic decision-making and speeds alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Dialysis Organization Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia prioritizes integration with major dialysis providers like DaVita and Fresenius Medical Care, which together treat about 70% of the US dialysis population—roughly 450,000 patients as of 2024—making them crucial distribution hubs.\u003c\/p\u003e\n\u003cp\u003eSecuring formulary placement and on-site stocking in these networks ensures Vafseo (vadadustat) is available at the point of care for the primary dialysis patient cohort, supporting uptake and predictable revenue streams tied to clinic utilization rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia distributes Auryxia through a select specialty pharmacy network trained for chronic kidney disease (CKD) care; as of 2025 about 70% of Auryxia prescriptions route via specialty pharmacies that offer counseling and benefits coordination, reducing abandonment by an estimated 25%. These pharmacies secure consistent supply for outpatient and home-managed CKD patients and support prior authorization and reimbursement, which helped Auryxia net $145 million in U.S. specialty-channel revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing via Mitsubishi Tanabe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia uses partners for non-US markets, reducing capex and compliance burden; Mitsubishi Tanabe Pharma handles vadadustat commercialization in Japan and parts of Asia under a license agreement signed in 2018, with potential royalties and milestone payments up to several hundred million dollars tied to approvals and sales.\u003c\/p\u003e\n\u003cp\u003eIn Japan, Mitsubishi Tanabe's established salesforce and regulatory track record cut launch costs and time-to-market; this partnership targets dialysis and non-dialysis CKD populations where 2024 estimates show Japan accounts for ~10% of global ESA (erythropoiesis-stimulating agent) spend.\u003c\/p\u003e\n\u003cp\u003eThe deal lets Akebia keep manufacturing and US commercialization focused while collecting tiered royalties, preserving cash: in 2023 Akebia reported partnering revenue as a material part of non-GAAP income, helping extend runway into late-stage H1 2025 programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesaler Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia holds national distribution contracts with AmerisourceBergen, Cardinal Health, and McKesson, covering \u0026gt;90% of US hospital and retail pharmacy channels as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese wholesalers provide logistics from manufacturing to point-of-care, handling ~80% of Akebia’s channel shipments and reducing stockouts to under 2% in 2024.\u003c\/p\u003e\n\u003cp\u003eActive relationship management—weekly forecasts, VMI (vendor-managed inventory), and quarterly KPIs—keeps nationwide inventory levels stable and supports 95% on-time delivery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: \u0026gt;90% of US channels\u003c\/li\u003e\n\u003cli\u003eShipments via wholesalers: ~80%\u003c\/li\u003e\n\u003cli\u003eStockout rate: \u0026lt;2% (2024)\u003c\/li\u003e\n\u003cli\u003eOn-time delivery: 95%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Formularies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpensuring placement on hospital and institutional formularies is central to akebia strategy enabling uninterrupted transition from inpatient outpatient renal care supporting adherence about of dialysis starts occur inpatient-to-outpatient so formulary presence matters. account managers engage pharmacy directors with data reduced readmission rates logistics citing contract wins that expanded coverage by\u003e \n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary access enables inpatient→outpatient continuity\u003c\/li\u003e\n\u003cli\u003e~65% dialysis transitions affected by formulary listing\u003c\/li\u003e\n\u003cli\u003e2024 institutional coverage up ~18%\u003c\/li\u003e\n\u003cli\u003eAccount managers target pharmacy directors with clinical\/logistics data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pensuring\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAkebia: Broad US dialysis reach, strong specialty \u0026amp; wholesale distribution, Japan partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia secures point-of-care availability via DaVita\/Fresenius (~70% US dialysis, ~450,000 pts 2024), specialty pharmacies (≈70% Auryxia scripts, 25% lower abandonment) and wholesalers (AmerisourceBergen\/Cardinal\/McKesson \u0026gt;90% channel coverage, ~80% shipments, \u0026lt;2% stockouts, 95% on-time). Partnerships (Mitsubishi Tanabe) cut launch cost in Japan (~10% global ESA spend) and provide tiered royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS dialysis coverage (DaVita+FMC)\u003c\/td\u003e\n\u003ctd\u003e~70% (~450,000 pts, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryxia via specialty pharmacy\u003c\/td\u003e\n\u003ctd\u003e~70% scripts; -25% abandonment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler channel coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% channels; ~80% shipments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout \/ On-time\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2% \/ 95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan ESA spend share\u003c\/td\u003e\n\u003ctd\u003e~10% global (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAkebia 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Akebia 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact, fully complete analysis—editable and ready to use for strategy, presentations, or implementation.\u003c\/p\u003e\n\u003cp\u003eThis is not a sample or demo; the file displayed is the final, high-quality deliverable included with your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750642332025,"sku":"akebia-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/akebia-marketing-mix.png?v=1772225667","url":"https:\/\/matrixbcg.com\/products\/akebia-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}